Company Monitoring Page for MorphoSys

job ratings for MorphoSys

05/10/21
industry:
pharmaceutical
job title:
MSL
company:
MorphoSys
job rating:
1
Horrible culture incompetent/vindictive/mean/management
05/28/20
industry:
pharmaceutical
job title:
Medical Science Liaison
company:
MorphoSys
job rating:
6
small biotech starting out exciting compared to being MSL for larger pharma companies.

latest headlines for company on cafepharma

Novartis may have bought MorphoSys, but it really only had eyes for BET inhibitor pelabresib: filing
Fierce Biotech
Fri, 04/12/24 - 11:23 am
Tags:
Novartis, MorphoSys, pelabresib, myelofibrosis, M&A, BET inhibitor
Novartis begins tender offer for cancer-focused MorphoSys
Reuters
Thu, 04/11/24 - 11:54 am
Tags:
Novartis, M&A, cancer, MorphoSys
7 Billion-Dollar Oncology M&As from Q1
BioSpace
Wed, 04/10/24 - 11:24 am
Tags:
oncology, M&A, AbbVie, Immunogen, Bristol Myers Squibb, Mirati Therapeutics, RayzeBio, Novartis, MorphoSys, AstraZeneca, Fusion Pharmaceuticals, JNJ, Ambrx, Gracell
Fierce Biotech's Quarterly IPO and M&A Roundup: Q1'24
Fierce Biotech
Wed, 04/3/24 - 11:36 am
Tags:
biotech, M&A, IPOs, CG Oncology, Kyverna Therapeutics, Contineum Therapeutics, Boundless Bio, CymaBay Therapeutics, Gilead Sciences, MorphoSys, Novartis, Fusion Pharmaceuticals, AstraZeneca, Ambryx, JNJ, Inhibrix, Aventis
Novartis in the lead to acquire cancer drug developer MorphoSys-sources
NASDAQ.com/Reuters
Mon, 02/5/24 - 11:28 am
Tags:
Novartis, M&A, MorphoSys, cancer
MorphoSys’ pelabresib meets endpoints in Phase III myelofibrosis trial
Clinical Trials Arena
Tue, 11/21/23 - 11:55 am
Tags:
MorphoSys, clinical trials, pelabresib, myelofibrosis
MorphoSys Cuts Pre-Clinical Programs, 17% of Staff
BioSpace
Thu, 03/2/23 - 10:46 pm
Tags:
MorphoSys, layoffs
Autoimmune drug biotech HI-Bio unveils $120M to root out cellular drivers of disease
MedCity News
Tue, 11/1/22 - 10:55 am
Tags:
Human Immunology Bioscience, autoimmune disease, R&D, MorphoSys, kidney disease
MorphoSys Adds HIBio to Busy Collaboration Week
BioSpace
Wed, 06/15/22 - 11:03 am
Tags:
MorphoSys, HIBio, Pfizer, Incyte
Opportunities arise for once-spurned partners
EP Vantage
Fri, 05/13/22 - 10:34 am
Tags:
Pfizer, Biohaven, licensing, M&A, Aurinia, Bristol Myers Squibb, AbbVie, Alector, Arcus Biosciences, Biogen, Blueprint Medicines, CureVac, Gilead Sciences, GSK, Incyte, MorphoSys, Roche, Nestle, SAGE Therapeutics, Sarepta Therapeutics, Seres Therapeutics, Syndax
MorphoSys cuts R&D from Constellation deal to focus on clinical-stage cancer drugs
MedCity News
Fri, 03/11/22 - 10:42 am
Tags:
MorphoSys, drug discovery, R&D, Constellation Pharmaceuticals, M&A
In a quiet year for takeouts, who was buying?
EP Vantage
Fri, 01/28/22 - 09:54 am
Tags:
M&A, Jazz Pharmaceuticals, Horizon Pharma, MorphoSys
BioMarin stands tall with first approved drug for rare disease that causes dwarfism
MedCity News
Sat, 08/28/21 - 08:57 pm
Tags:
Biomarin, Europe, achondroplasia, dwarfism, Incyte, MorphoSys
Biotech M&A tracker: After hitting new heights, deals have slowed down. Here are the latest.
BioPharma Dive
Tue, 08/10/21 - 11:12 pm
Tags:
M&A, Bayer, Sanofi, Amgen, uniQure, MorphoSys, Xeris Pharmaceuticals, Relay Therapeutics, Merck, Beam Therapeutics, Jazz Pharmaceuticals
Biopharma takeovers dry up
EP Vantage
Mon, 07/5/21 - 09:50 pm
Tags:
M&A, MorphoSys, Constellation Pharmaceuticals, Sanofi, Tidal Therapeutics, uniQure, Corlieve Therapeutics, Strongbridge Biopharma, Xerix Pharmaceuticals, Novellus Therapeutics, Brooklyn Immunotherapeutics
Morphosys to buy Constellation in $1.7B deal, aided by unusual funding
BioPharma Dive
Wed, 06/2/21 - 12:10 pm
Tags:
MorphoSys, M&A, Constellation Pharmaceuticals
OptumRx's 3 recently approved drugs to watch
Beckers Hospital Review
Tue, 09/22/20 - 10:15 pm
Tags:
FDA, Kite Pharma, Tecartus, Novartis, Kesimpta, MorphoSys, Monjuvi, OptumRx
FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population
MedCity News
Mon, 08/3/20 - 10:14 am
Tags:
FDA, Monjuvi, CAR-T, MorphoSys, Incyte, diffuse large B-cell lymphoma
Morphosys’ off-the-shelf rival to CAR-T approaches finish line with a speedy review
Endpoints
Mon, 03/2/20 - 09:37 am
Tags:
MorphoSys, Gilead Sciences, Novartis, CAR-T, tafasitamab, DLBCL
Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug
Xconomy
Mon, 01/13/20 - 11:51 pm
Tags:
Incyte, MorphoSys, lymphoma, tafasitamab

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.